Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- APRE
- Price
- 0.60
- Stock movement down
- -0.06 (-7.35%)
- Company name
- Aprea Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.30M
- Ent value
- -5.74M
- Price/Sales
- 10.86
- Price/Book
- 0.46
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -52.12%
- 1 year return (CAGR)
- -74.91%
- 3 year return (CAGR)
- -54.79%
- 5 year return (CAGR)
- -65.06%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
APRE does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 10.86 |
| Price to Book | 0.46 |
| EV to Sales | -11.75 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.99M |
| EPS (TTM) | -2.05 |
| FCF per share (TTM) | -2.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 488.24K |
| Gross profit (TTM) | -6.27M |
| Operating income (TTM) | -13.82M |
| Net income (TTM) | -13.04M |
| EPS (TTM) | -2.05 |
| EPS (1y forward) | -0.91 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1284.53% |
| Operating margin (TTM) | -2829.92% |
| Profit margin (TTM) | -2670.56% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 13.72M |
| Net receivables | 0.00 |
| Total current assets | 13.94M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 65.24K |
| Total assets | 14.32M |
| Accounts payable | 641.32K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.68M |
| Total liabilities | 2.68M |
| Shareholder's equity | 11.64M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -13.54M |
| Capital expenditures (TTM) | 381.00 |
| Free cash flow (TTM) | -13.54M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -112.01% |
| Return on Assets | -91.04% |
| Return on Invested Capital | -112.01% |
| Cash Return on Invested Capital | -116.29% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.81 |
| Daily high | 0.84 |
| Daily low | 0.71 |
| Daily Volume | 253K |
| All-time high | 990.60 |
| 1y analyst estimate | 5.33 |
| Beta | 1.61 |
| EPS (TTM) | -2.05 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| APRE | S&P500 | |
| Current price drop from All-time high | -99.94% | -1.82% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 13 Feb 2023 | 9 Mar 2009 |
| Avg drop from high | -84.69% | -10.84% |
| Avg time to new high | 107 days | 12 days |
| Max time to new high | 1545 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.30M
Marketcap category
Small-cap
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Employees
8
Website
Investor relations
-
SEC filings
CEO
Christian S. Schade
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page